phase 2_initiation
saveNational Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)
community read0 votes
Therapy area: Oncology. Indication: Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma
Data sources
globaldata
Found something off?
drug timeline · 8
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalFeb 12, 2026 · 239d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJan 27, 2026 · 255d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 19, 2025 · 324d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 14, 2025 · 329d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 6, 2025 · 337d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJul 30, 2024 · 801d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 2, 2022 · 1437d ago
- approvalDARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJan 21, 2022 · 1722d ago
same company · ±60 days · 6
- phase 2 completionipilimumab: National Cancer Institute US — ipilimumab (Phase II Trial Completion)Apr 30, 2026
- phase 1 completionundisclosed chemotherapy: National Cancer Institute US — undisclosed chemotherapy (Phase I Trial Completion)Apr 28, 2026
- phase 1 completiontuvusertib: National Cancer Institute US — tuvusertib (Phase I Trial Completion)Apr 30, 2026
- phase 1 completionemavusertib hydrochloride: National Cancer Institute US — emavusertib hydrochloride (Phase I Trial Completion)Apr 30, 2026
- phase 1 2 initiationPEP-CMV: National Cancer Institute US — PEP-CMV (Phase I/II Trial Initiation)Apr 30, 2026
- phase 2 initiationbusulfan: National Cancer Institute US — busulfan (Phase II Trial Initiation)Apr 27, 2026
🐶 often sniffed alongside
top 8- drugdaratumumab31 co-mentions · 16 sources
- drugdaratumumab + Gene Therapy31 co-mentions · 16 sources
- drugDARZALEX FASPRO30 co-mentions · 15 sources
- tagApproval30 co-mentions · 15 sources
- companyJanssen Biotech Inc15 co-mentions · 15 sources
- tagOncology2 co-mentions · 1 sources
- tagMultiple Myeloma2 co-mentions · 1 sources
- companyNational Cancer Institute US1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that